Overexpression of GOLPH3 protein is associated with worse prognosis in patients with epithelial ovarian cancer

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 11845-11849

  Ma, Yingchun ^a,b   Wang, Xiuxia ^b   Wu, Yuanhong ^c   Sun, Binghui ^a   Lv, Hongtao ^a   Rong, Fengnian ^a   Zheng, Xiaoxia ^d  

^a SHANDONG UNIVERSITY   (China)

^b LIAOCHENG PEOPLE'S HOSPITAL   (China)

^c Jinan Shizhong People s Hospital   (China)

^d JINAN MATERNITY AND CHILD CARE HOSPITAL   (China)

Author keywords

Epithelial ovarian cancer; Golgi phosphoprotein 3; Prognosis

Indexed keywords

GOLGI PHOSPHOPROTEIN 3; PHOSPHOPROTEIN; UNCLASSIFIED DRUG; GOLPH3 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

ADULT; AGED; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84923145885     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2411-1     Document Type: Article

References (32)

1. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol. 2009;4(1):287–313.
2. Wang Y, Wang D, Ren M. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis. Tumor Biol. 2014;35(1):33–8.
3. Kandalaft LE, Motz GT, Duraiswamy J, Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev. 2011;30(1):141–51.
4. Wu XJ, Yuan P, Li ZY, Bu ZD, Zhang LH, Wu AW, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patietns with ovarian metastasis and peritoneal dissemination. Tumor Biol. 2013;34(1):463–9.
5. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361(2):170–7.
6. Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 2011;12(12):1169–74.
7. Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer. 2010;10(5):371–8.
8. Karam AK, Karlan BY. Ovarian cancer: the duplicity of ca125 measurement. Nat Rev Clin Oncol. 2010;7(6):335–9.
9. Chen MB, Wu XY, Yu R, Li C, Wang LQ, Shen W, et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS ONE. 2012;7(9):e45388.
10. Kemal Y, Demirag G, Ekiz K, Yucel I. Mean platelet volume could be a useful biomarker for monitoring epithelial ovarian cancer. J Obstet Gynaecol. 2014;15(1):1–4.
11. Caceres-Gorriti KY, Carmona E, Barres V, Rahimi K, Letouneau IJ, Tonin PN, et al. RAN necleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer. PLoS ONE. 2014;9(3):e91000.
12. Chen WT, Gao X, Han XD, Zheng H, Guo L, Lu RQ. HE4 as a serum biomarker for ROMA prediction and prodiction and prognosis of epithelial ovarian cancer. Asian Pac J Cancer Prev. 2014;15(1):101–5.
13. Scott KL, Chin L. Signaling from the golgi: mechanisms and models for golgi phosphoprotein 3-mediated oncogenesis. Clin Cancer Res. 2010;16(8):2229–34.
14. Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, et al. Golph3 modulates mtor signalling and rapamycin sensitivity in cancer. Nature. 2009;459(7250):1085–90.
15. Dippold HC, Ng MM, Farber-Katz SE, Lee SK, Kerr ML, Peterman MC, et al. Golph3 bridges phosphatidylinositol-4- phosphate and actomyosin to stretch and shape the golgi to promote budding. Cell. 2009;139(2):337–51.
16. Farber-Katz SE, Dippold HC, Buschman MD, Peterman MC, Xing M, Noakes CJ, et al. DNA damage triggers golgi dispersal via DNA-PK and GOLPH3. Cell. 2014;156(3):413–27.
17. Xue Y, Wu G, Liao Y, Xiao G, Ma X, Zou X, et al. Golph3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma. Br J Cancer. 2014;110(9):2250–60.
18. Zeng Z, Lin H, Zhao X, Liu G, Wang X, Xu R, et al. Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the foxo1 transcription factor. Clin Cancer Res. 2012;18(15):4059–69.
19. Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, et al. Increased expression of golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol. 2012;7(1):127.
20. Zhou J, Xu T, Qin R, Yan Y, Chen C, Chen Y, et al. Overexpression of golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. J Neurooncol. 2012;110(2):195–203.
21. Hu BS, Hu H, Zhu CY, Gu YL, Li JP. Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour Biol. 2013;34(1):515–20.
22. Ma Y, Ren Y, Zhang X, Lin L, Liu Y, Rong F, et al. High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma. Virchows Arch. 2014;464(4):443–52.
23. Farber-Katz SE, Dippold HC, Buschman MD, Peterman MC, Xing M, Noakes CJ, et al. DNA damage triggers Golgi dispersal via DNA-PK and GOLPH3. Cell. 2014;156(3):413–27.
24. Li H, Guo L, Chen SW, Zhao XH, Zhuang SM, Wang LP, et al. GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer. J Transl Med. 2012;10(1):168.
25. Cao J, Cai J, Huang D, Han Q, Chen Y, Yang Q, et al. Mir-335 represents an independent prognostic marker in epithelial ovarian cancer. Am J Clin Pathol. 2014;141(3):437–42.
26. Liu T, Gao H, Chen X, Lou G, Gu L, Yang M, et al. TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer. Br J Cancer. 2013;109(6):1685–92.
27. Lee JY, Myung SK, Song YS. Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies. Gynecol Oncol. 2013;129(3):613–9.
28. Taft MH, Behrmann E, Munske-Weidemann LC, Thiel C, Raunser S, Manstein DJ. Functional characterization of human myosin-18A and its interaction with F-actin and GOLPH3. J Biol Chem. 2013;288(42):30029–41.
29. Chang WL, Chang CW, Chang YY, Sung HH, Lin MD, Chang SC, et al. The Drosophila GOLPH3 homolog regulates the biosynthesis of heparan sulfate proteoglycans by modulating the retrograde trafficking of exostosins. Development. 2013;140(13):2798–807.
30. Sechi S, Colotti G, Belloni G, Mattei V, Frappaolo A, Raffa GD, et al. GOLPH3 is essential for contractile ring formation and Rab11 localization to the cleavage site during cytokinesis in Drosophila melanogaster. PLoS Genet. 2014;10(5):e1004305.
31. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Besenbacher S, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011;43(11):1104–7.
32. Glienke W, Maute L, Wicht J, Bergmann L. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Tumor Biol. 2012;33(3):757–65.